Upgrade to Finviz Elite: Get our fastest platform speed, real-time data, and unlimited screening & charting. Start Free Trial

LTRN

Lantern Pharma Inc

Apr 24 • 04:00PM ET

2.46

+0.15 6.49 %

Healthcare • Biotechnology • USA • NASD

Peers: EXAI DNLI FATE IMTX KRYS RAPT RPTX XERS ARDX

| Held by: VTI VXF MEDX IWC DFSU DFAC DCOR

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-1.57	Insider Own	26.16%	Shs Outstand	11.25M	Perf Week	-1.20%
Market Cap	27.57M	Forward P/E	-	EPS next Y	-2.02	Insider Trans	0.00%	Shs Float	8.28M	Perf Month	10.81%
Enterprise Value	17.53M	PEG	-	EPS next Q	-0.36	Inst Own	11.34%	Short Float	21.03%	Perf Quarter	-28.90%
Income	-17.12M	P/S	-	EPS this Y	-10.83%	Inst Trans	0.40%	Short Ratio	3.06	Perf Half Y	-36.76%
Sales	0.00M	P/B	4.24	EPS next Y	-16.09%	ROA	-93.52%	Short Interest	1.74M	Perf YTD	-18.81%
Book/sh	0.58	P/C	2.72	EPS next 5Y	-10.36%	ROE	-123.51%	52W High	5.74 -57.17%	Perf Year	-32.04%
Cash/sh	0.90	P/FCF	-	EPS past 3/5Y	-6.13% -10.59%	ROIC	-262.00%	52W Low	1.11 121.62%	Perf 3Y	-46.98%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-	Volatility	15.08% 21.87%	Perf 5Y	-85.14%
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	18.69%	Oper. Margin	-	ATR (14)	0.31	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	2.40	Sales Y/Y TTM	-	Profit Margin	-	RSI (14)	54.69	Recom	1.00
Dividend Gr. 3/5Y	- -	Current Ratio	2.40	EPS Q/Q	33.55%	SMA20	20.54%	Beta	2.21	Target Price	22.67
Payout	-	Debt/Eq	0.01	Sales Q/Q	-	SMA50	4.55%	Rel Volume	0.41	Prev Close	2.31
Employees	16	LT Debt/Eq	0.00	Earnings	Mar 30 AMC	SMA200	-29.04%	Avg Volume	568.93K	Price	2.46
IPO	Jun 11, 2020	Option/Short	Yes / Yes	EPS/Sales Surpr.	21.74% -	Trades		Volume	233,709	Change	6.49%

Date	Action	Analyst	Rating Change	Price Target Change
Oct-07-21	Initiated	H.C. Wainwright	Buy	$32

Today 07:50AM	Lantern Pharma to Debut Public Demonstration of withZeta.ai - A Platform to Conquer Rare Cancers on April 30 Following AACR 2026 Scientific Debut (Business Wire) +6.49%
Apr-14-26 08:31AM	Lantern Pharma Launches withZeta.ai the Worlds First Multi-Agentic A.I. Co-Scientist for Rare Cancer Drug Discovery & Development Subscriptions Now Open; Debut Events at Nasdaq MarketSite on 4/16 and at AACR 2026 from 4/17 to 4/22 (Business Wire)
Apr-02-26 09:00PM	Lantern Pharma Inc (LTRN) Q4 2025 Earnings Call Highlights: Strategic Advances Amid Financial ... (GuruFocus.com) +14.08%
08:10AM	Lantern Pharma Invites Investors, Analysts & Shareholders to Experience the Future of Drug Discovery via a Live Demo of withZeta.ai the World's First Multi-Agentic Co-Scientist for Rare Cancers 8:30 AM Eastern, April 9, 2026 (Business Wire)
Mar-30-26 04:05PM	Lantern Pharma Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Updates (Business Wire) +10.27% +10.93%
07:29AM	Loading…
Mar-27-26 07:29AM	Lantern Pharma and Starlight Therapeutics Announce FDA Clearance of IND for a Planned Phase 1 Pediatric CNS Cancer Trial of STAR-001 (Business Wire) -46.41%
Mar-23-26 04:30PM	Lantern Pharma to Report Fourth Quarter and Fiscal Year 2025 Operating & Financial Results on March 30th, 2026 at 4:30 p.m. ET (Business Wire) +5.16%
Feb-12-26 11:19AM	Lantern Pharma (LTRN) Advances Oncology AI and Gains Orphan Drug Recognition (Insider Monkey) -5.61%
Feb-10-26 08:45AM	Lantern Pharma to Present at the 7th Glioblastoma Drug Development Summit in Boston on February 17-19, 2026 (Business Wire) +7.38%
Jan-20-26 08:00AM	Lantern Pharma's LP-284 Receives FDA Orphan Drug Designation for Soft Tissue Sarcomas (Business Wire)
Jan-12-26 09:00AM	Lantern Pharma Announces Establishing an A.I. Center of Excellence in India to Industrialize the RADR Platform and Accelerate Global Development Opportunities with BioPharma Companies (Business Wire)
Dec-03-25 08:35AM	Lantern Pharma Reports Additional Positive LP-184 Phase 1a Results Showing Durable Disease Control in Heavily Pre-Treated Advanced Cancer Patients as Company Advances Precision Oncology Program into Multiple Biomarker-Guided Phase 1b/2 Trials (Business Wire)
Nov-13-25 08:30AM	Lantern Pharma Reports Third Quarter 2025 Financial Results and Provides Business Updates (Business Wire)
Nov-06-25 08:00AM	Lantern Pharma to Report Third Quarter 2025 Operating & Financial Results on November 13th, 2025 at 9:00 a.m. ET (Business Wire) -5.35%
Oct-30-25 08:00AM	Lantern Pharma to Present AI-Driven Cancer Drug Development & Research Platforms at Inaugural AI for Biology and Medicine Symposium at UNT (Business Wire)
08:49AM	Loading…
Oct-28-25 08:49AM	Lantern Pharma Presents LP-284 Clinical Data at 25th LL&M Congress, Highlighting Complete Response in Therapeutically Exhausted DLBCL Patient & Therapeutic Potential in Advanced B-Cell Cancers. (Business Wire)
Oct-24-25 08:00AM	Lantern Pharma to Present at the ThinkEquity Conference in NYC on October 30, 2025 (Business Wire) +10.27%
Sep-16-25 08:29AM	Lantern Pharmas LP-184 Phase 1a Clinical Trial Achieves All Primary Endpoints with Robust Safety Profile and Promising Antitumor Activity in Multiple Advanced Solid Tumors (Business Wire) +7.61%
Sep-03-25 09:44AM	Lantern Pharma Announces Completion of Type C Meeting with FDA, Providing Clarity on Regulatory Pathway for Pediatric CNS Cancer Trial (Business Wire) +6.45%
Aug-13-25 04:30PM	Lantern Pharma Reports Second Quarter 2025 Financial Results and Business Updates (Business Wire) +6.97%
Aug-07-25 05:34AM	FDA clears Starlight Therapeutics IND for Phase Ib/IIa glioblastoma trial (Clinical Trials Arena)
Aug-06-25 08:30AM	Lantern Pharma's Subsidiary, Starlight Therapeutics, Announces U.S. Food and Drug Administration Clearance of IND for Phase Ib/2a Glioblastoma Multiforme (GBM) Trial (Business Wire)
Aug-04-25 08:55AM	Lantern Pharma Announces Public Release of Transformative, Advanced AI Module for Blood-Brain Barrier Permeability Prediction, predictBBB.ai (Business Wire) +11.53%
Aug-01-25 05:45AM	Lantern Pharma concludes patient enrolment for trial of LP-300 in Japan (Clinical Trials Arena) +7.43%
Jul-31-25 07:30AM	Lantern Pharma Completes Targeted Enrollment for Lung Cancer Phase 2 Harmonic Clinical Trial in Japan for LP-300 (Business Wire) +10.72%
Jul-28-25 08:00AM	Lantern Pharma Announces Appointment of Dr. Lee Schalop to Board of Directors (Business Wire) -5.31%
Jul-23-25 07:56AM	Lantern Pharma Reports Complete Response in Heavily Pre-Treated Lymphoma Patient with LP-284 in Phase 1 Clinical Trial (Business Wire)
Jul-21-25 08:20AM	Lantern Pharma Secures EU Patent Allowance for LP-284, Bolstering Global IP Position for AI-Developed Cancer Therapy (Business Wire) -5.01%
Jul-16-25 08:30AM	IBN Initiates Coverage of Lantern Pharma Inc. (GlobeNewswire) +6.12%
Jul-15-25 09:40AM	Lantern Pharma Unveils Groundbreaking AI-Powered Module to Predict Activity and Efficacy of Combination Regimens in Clinical Cancer Treatment (Business Wire) -5.76%
08:30AM	Loading…
Jun-16-25 08:30AM	Lung Cancer Patient in Lantern Pharma's Harmonic Trial Shows Durable Complete Response in Target Cancer Lesions with Survival Continuing for Nearly Two Years (Business Wire)
May-29-25 11:21PM	Lantern Pharma Inc. (LTRN)'s LP-184 Shows 345% Survival Gain in Rare Pediatric Brain Tumor Models (Insider Monkey) +9.06%
08:30AM	Lantern Pharma's LP-184 Shows Promising In Vivo Activity in Atypical Teratoid Rhabdoid Tumors (ATRT) at SNO Pediatric Conference, Further Validating Rare Pediatric Disease Designation and Pathway to Clinical Trials (Business Wire)
May-15-25 08:45AM	Lantern Pharma Reports First Quarter 2025 Financial Results and Business Updates (Business Wire)
May-12-25 09:00AM	Lantern Pharma Secures FDA Clearance for Planned Phase 1b/2 Trial of LP-184 in Biomarker-Defined, Treatment-Resistant NSCLC Patients with High Unmet Clinical Need (Business Wire)
08:31AM	EXCLUSIVE: FDA Clears Lantern Pharma's Planned Phase 1b/2 Trial of LP-184 In Treatment-Resistant Lung Cancer Patients (Benzinga)
May-08-25 08:30AM	Lantern Pharma to Report First Quarter 2025 Operating & Financial Results on May 15th, 2025 at 9:00 a.m. ET (Business Wire) -11.06%
May-05-25 08:55AM	Lantern Advances Drug Candidate LP-184 with IND Clearance for Phase 1b/2 Clinical Trial in Triple Negative Breast Cancer (TNBC) (Business Wire)
08:31AM	EXCLUSIVE: Lantern Advances Breast Cancer Drug Candidate With FDA Clearance For Early-Stage Trial (Benzinga)
Apr-01-25 09:01PM	Lantern Pharma Inc (LTRN) Q4 2024 Earnings Call Highlights: Navigating Growth and Challenges (GuruFocus.com) -6.50%
Mar-27-25 08:35PM	Lantern Pharma Inc. (LTRN) Q4 2024 Earnings Call Transcript (Seeking Alpha)
04:01PM	Lantern Pharma Provides Business Updates and Fourth Quarter & Year-End 2024 Financial Results (Business Wire)
Mar-20-25 08:00AM	Lantern Pharma to Report Fourth Quarter and Fiscal Year 2024 Operating & Financial Results on March 27th, 2025 at 4:30 p.m. ET (Business Wire)
Mar-12-25 06:00AM	How long-term energy plays outshine short-term hype (Yahoo Finance Video) +7.56%
Feb-20-25 04:14PM	Lantern Pharma (LTRN) Files Patent for AI-Powered Blood-Brain Barrier Prediction Tech (Insider Monkey) -6.68%
Feb-19-25 08:00AM	Lantern Pharma Announces PCT Patent Application Publication for Innovative, High Performing, Machine Learning Model for Predicting Blood Brain Barrier Permeability of Drug-Candidates (Business Wire)
Jan-27-25 06:54PM	Lantern Pharma Inc. (LTRN) Enhances RADR® AI Platform to Accelerate Development of Antibody-Drug Conjugates (ADCs) for Targeted Cancer Therapies (Insider Monkey) -15.00%
07:55AM	Lantern Pharma Unveils Innovative AI-Powered Module to Improve the Precision, Cost and Timelines of Antibody-Drug Conjugate (ADC) Development for Cancer (Business Wire)
Jan-17-25 01:29PM	Lantern Pharma Inc. (LTRN): AI-Driven Cancer Drug Development (Insider Monkey)
Dec-10-24 10:40AM	AI-Powered Cancer Solutions: Lantern Pharma (LTRN) Launches Phase 2 Trial in Taiwan (Insider Monkey)
Dec-09-24 12:21PM	Lantern Pharma starts dosing in Taiwan in non-smoker lung cancer trial (Clinical Trials Arena)
08:15AM	Lantern Pharma Announces First Patient Enrolled in Taiwan for Phase 2 HARMONIC Clinical Trial of LP-300 in Never-Smoker NSCLC Patients (Business Wire)
Dec-07-24 01:59AM	Lantern Pharma Inc. (LTRN) Receives Second FDA Fast Track Designation for LP-184 in Triple Negative Breast Cancer (Insider Monkey)
Dec-03-24 08:00AM	Lantern Pharma's Investigational Drug-Candidate, LP-184, Receives Second Fast Track Designation from FDA for Treatment of Triple Negative Breast Cancer (TNBC) (Business Wire)
Nov-26-24 08:45AM	Lantern Pharma and Starlight Therapeutics Present LP-184 (STAR-001) Phase 1b Trial Design and Preclinical Data in Glioblastoma at Society for Neuro-Oncology (SNO) 2024 Highlighting Novel Synthetic Lethality (Business Wire)
Nov-19-24 08:00AM	Lantern Pharma Announces First Patient Dosed in Japan for The Expansion Cohort in The Phase 2 HARMONIC Clinical Trial of LP-300 in Never-Smoker NSCLC Patients (Business Wire)
Nov-08-24 06:03PM	Lantern Pharma Inc (LTRN) Q3 2024 Earnings Call Highlights: Strategic Advances Amid Rising ... (GuruFocus.com) +12.28% -8.59%
Nov-07-24 04:05PM	Lantern Pharma Reports Third Quarter 2024 Financial Results and Business Updates (Business Wire)
Nov-05-24 08:00AM	Starlight Therapeutics Announces Inaugural Members of Scientific Advisory Board (Business Wire)
Oct-31-24 08:00AM	Lantern Pharma to Report Third Quarter 2024 Operating & Financial Results on November 7th, 2024 at 4:30 p.m. ET (Business Wire)
Oct-23-24 08:45AM	Lantern Pharma to Present at the ThinkEquity Conference in NYC on October 30, 2024 (Business Wire)
Oct-21-24 08:00AM	Lantern Pharma to Host & Participate in Two Public Webinars During October (Business Wire)
Oct-15-24 09:07AM	Lantern Pharmas Investigational Drug-Candidate, LP-184, Receives Fast-Track Designation in Glioblastoma from the FDA (Business Wire)
Oct-09-24 05:56PM	Lantern Pharma Inc (LTRN) Q2 2024 Earnings Call Highlights: Promising Clinical Trials and ... (GuruFocus.com)
Sep-23-24 08:00AM	Lantern Pharma Announces Three U.S. FDA Rare Pediatric Disease Designations Granted to LP-184 in Multiple Ultra Rare Childrens Cancers (Business Wire)
Aug-31-24 02:02PM	Lantern Pharma Inc. (LTRN): A Penny Stock That Will Make You a Millionaire (Insider Monkey)
Aug-08-24 04:01PM	Lantern Pharma Reports Second Quarter 2024 Financial Results and Business Updates (Business Wire) -7.68%
Aug-07-24 09:31AM	Lantern Pharma Highlights Promising Preclinical Results of LP-184's Synergy with Checkpoint Inhibitors & Sensitizing Tumors That are Non-Responsive to Anti-PD1 Therapy in Collaboration with MD Anderson at Immuno-Oncology Summit 2024 (Business Wire) +12.26%
Aug-05-24 08:00AM	Lantern Pharma Announces Positive Clinical Update from Ongoing Phase 2 HARMONIC Clinical Trial for Never Smokers with Advanced NSCLC, Including an 86% Clinical Benefit Rate in the Initial Patient Cohort (Business Wire) -5.88%
Aug-01-24 08:00AM	Lantern Pharma to Report Second Quarter 2024 Operating & Financial Results on August 8th, 2024 at 4:30 p.m. ET (Business Wire)
Jul-10-24 08:30AM	Lantern Pharma Achieves Key Milestone Towards Development of Molecular Diagnostic for use in Oncology Clinical Trials for Patient Selection and Stratification with Drug Candidate LP-184 (Business Wire)
Jun-12-24 07:30AM	Lantern Pharma Receives Certificate of Patent from Japanese Patent Office (JPO) for Composition of Matter Covering Drug Candidate LP-284 (Business Wire)
May-23-24 11:51AM	Pancreatic Cancer Battle Intensifies: Biotech Innovations Aim to Boost Survival Rates (PR Newswire)
May-09-24 04:02PM	Lantern Pharma Reports First Quarter 2024 Financial Results and Business Highlights (Business Wire) +5.09% -9.54%
May-06-24 06:41AM	Lantern Pharma and Oregon partner to develop cancer treatment (Pharmaceutical Technology) +11.38%
04:37AM	Lantern Pharma, Oregon Therapeutics Partner to Develop AI-Driven Cancer Drug Collaboration (MT Newswires)
03:00AM	Oregon Therapeutics & Lantern Pharma Launch Strategic AI Collaboration to Optimize Development of First-In-Class Drug Candidate XCE853 A Potent Inhibitor of Cancer Metabolism (Business Wire)
May-02-24 07:30AM	Lantern Pharma to Report First Quarter 2024 Operating & Financial Results on May 9th, 2024 at 4:30 p.m. ET (Business Wire)
May-01-24 06:00AM	3 Machine Learning Stocks with the Potential to Make You an Overnight Millionaire (InvestorPlace) +5.69%
Apr-24-24 08:00AM	Lantern Pharma Launches "Webinar Wednesdays" Featuring World-Class Physician Scientists & Key Opinion Leaders Discussing Critical Areas of Oncology Drug Development (Business Wire) -6.76%
Apr-22-24 08:12AM	Lantern Pharma Receives Regulatory Approval to Expand Harmonic Clinical Trial for Non-Small Cell Lung Cancer in Never-Smokers into Japan and Taiwan (Business Wire) +7.12%
Apr-10-24 08:45AM	Software Segment of Global A.I. Healthcare Billion Dollar Market Expected to Have Fastest Growth (PR Newswire)
Mar-20-24 09:00AM	Global A.I. Medical Diagnostics Market Poised To Reach $3.7 Billion By 2028 (GlobeNewswire) +17.49%
Mar-19-24 09:06AM	Lantern Pharma Inc. (NASDAQ:LTRN) Q4 2023 Earnings Call Transcript (Insider Monkey) -24.80%
Mar-18-24 08:53PM	LTRN Stock Earnings: Lantern Pharma Beats EPS for Q4 2023 (InvestorPlace) +14.48%
05:32PM	Lantern Pharma Inc Reports Progress and Financials for FY 2023 (GuruFocus.com)
04:02PM	Lantern Pharma Reports Fourth Quarter & Fiscal Year 2023 Financial Results and Business Highlights (Business Wire)
Mar-15-24 08:00AM	Lantern Pharma Announces Initial Patients Dosed in First-In-Human Clinical Trial for AI-Guided Drug-Candidate, LP-284 (Business Wire) +18.37%
Mar-11-24 07:30AM	Lantern Pharma to Report Fourth Quarter and Fiscal Year 2023 Operating & Financial Results on March 18th, 2024 at 4:30 p.m. ET (Business Wire) -23.58%
Mar-07-24 06:17AM	11 Best Artificial Intelligence Stocks Under $20 According To Hedge Funds (Insider Monkey) +21.13%
Mar-05-24 08:01AM	Lantern To Participate in H.C Wainwright & Co.s (HCW) 1st Annual Artificial Intelligence Based Drug Discovery & Development Virtual Conference (Business Wire) +5.95%
Mar-04-24 08:01AM	Lantern Pharma's A.I. Platform, RADR, Surpasses 60 Billion Data Points Anticipates Reaching 100 Billion Data Points in 2024, Paving the Way for Enhanced Cancer Therapy Innovations and Expedited Development Timelines (Business Wire) +9.40%
Feb-20-24 08:01AM	3 AI Powerhouses Predicted to Soar 500% in the Next Tech Boom (InvestorPlace)
Feb-15-24 08:01AM	Lantern Pharma Advances Unique ADC (Antibody Drug Conjugate) Program Across Multiple Solid Tumor Cancers (Business Wire)
Jan-17-24 07:30AM	Starlight Therapeutics, a Subsidiary of Lantern Pharma Focused on CNS & Brain Cancers, Announces Dr. Marc Chamberlain as Chief Medical Officer (Business Wire)
Dec-13-23 08:05AM	The 3 Most Undervalued AI Penny Stocks to Buy in December (InvestorPlace)
Nov-30-23 08:00AM	FDA Grants Lantern Pharma Orphan Drug Designation for Drug Candidate LP-284 in High-Grade B-cell Lymphomas (HGBL) (Business Wire)
Nov-10-23 11:31AM	Lantern Pharma Inc. (NASDAQ:LTRN) Q3 2023 Earnings Call Transcript (Insider Monkey) -11.53%
Nov-08-23 06:43PM	Lantern Pharma Inc (LTRN) Reports Q3 2023 Financial Results and Provides Operational Updates (GuruFocus.com) +33.21%
04:01PM	Lantern Pharma Reports Third Quarter 2023 Financial Results and Operational Highlights (Business Wire)

Lantern Pharma, Inc. engages in the development of drugs through leveraging artificial intelligence, machine learning, and genomic data. Its portfolio includes LP-100, LP-300, and LP-184. The company was founded by Arun K. Asaithambi, Gregory T. Tobin, and Peter L. Nara on November 7, 2013 and is headquartered in Dallas, TX.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Fletcher Aaron G.L.	10% Owner	Jun 13 '25	Sale	3.09	40,000	123,600	49,957	Jun 13 07:57 PM
Kreis Leslie W.	10% Owner	Jun 13 '25	Sale	3.09	40,000	123,600	49,957	Jun 13 07:50 PM
Fletcher Aaron G.L.	10% Owner	Jun 12 '25	Sale	3.38	60,647	204,987	51,860	Jun 13 06:06 AM
Fletcher Aaron G.L.	10% Owner	Jun 11 '25	Sale	3.40	950	3,230	54,746	Jun 13 06:06 AM
Fletcher Aaron G.L.	10% Owner	Jun 10 '25	Sale	3.40	16	54	54,791	Jun 13 06:06 AM
Kreis Leslie W.	10% Owner	Jun 12 '25	Sale	3.38	60,647	204,987	51,860	Jun 13 06:01 AM
Kreis Leslie W.	10% Owner	Jun 11 '25	Sale	3.40	950	3,230	54,746	Jun 13 06:01 AM
Kreis Leslie W.	10% Owner	Jun 10 '25	Sale	3.40	16	54	54,791	Jun 13 06:01 AM
Fletcher Aaron G.L.	10% Owner	May 27 '25	Sale	3.05	21,037	64,163	56,467	May 29 09:55 PM
Fletcher Aaron G.L.	10% Owner	May 29 '25	Sale	3.03	20,200	61,206	54,792	May 29 09:55 PM
Fletcher Aaron G.L.	10% Owner	May 28 '25	Sale	2.87	15,000	43,050	55,753	May 29 09:55 PM
Kreis Leslie W.	10% Owner	May 27 '25	Sale	3.05	21,037	64,163	56,467	May 29 09:53 PM
Kreis Leslie W.	10% Owner	May 29 '25	Sale	3.03	20,200	61,206	54,792	May 29 09:53 PM
Kreis Leslie W.	10% Owner	May 28 '25	Sale	2.87	15,000	43,050	55,753	May 29 09:53 PM
Bios Fund II, LP	Affiliate (10% owner)	May 27 '25	Proposed Sale	3.29	53,454	175,864		May 27 09:00 PM
Bios Fund I QP, LP	Affiliate (10% owner)	May 27 '25	Proposed Sale	3.29	29,576	97,305		May 27 08:58 PM
Bios Fund II NT, LP	Affiliate (10% owner)	May 27 '25	Proposed Sale	3.29	25,849	85,033		May 27 08:56 PM
Bios Fund I, LP	Affiliate (10% owner)	May 27 '25	Proposed Sale	3.29	75,941	249,846		May 27 08:55 PM
Bios Fund II QP, LP	Affiliate (10% owner)	May 27 '25	Proposed Sale	3.29	105,180	346,042		May 27 08:53 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

LTRN

Lantern Pharma Inc

Upgrade your Finviz experience